CytoArm Co., Ltd
- Biotech or pharma, therapeutic R&D
CytoArm has developed a next-generation, non-genetically engineered T cell platform (Armed-T) for the treatment of solid tumors and autoimmune diseases. Our one-step, virus-free manufacturing process delivers over 90% pure, tumor-specific T cells within 10 days—offering a scalable, safe, and cost-effective alternative to CAR-T.
We are actively seeking strategic partners for pre-A funding, licensing, and co-development collaborations to advance our global clinical pipeline.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}